Report ID: SQMIG35H2239
CNS (Central Nervous System) Therapeutics Market Size, Share, Growth Analysis, By Disease(Neurovascular Diseases, CNS Trauma, Mental Health ( Anxiety Disorders, Epilepsy), By Drug Class(Analgesics, Antidepressants, Anesthetics, Anti-Parkinson Drugs), By Distribution Channel(Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies), By Region - Industry Forecast 2025-2032
Report ID:
SQMIG35H2239 |
Region:
Global |
Published Date: March, 2024
Pages:
219
|
Tables:
96 |
Figures:
76
CNS (Central Nervous System) Therapeutics Market News
-
In June 2022, CNS Pharmaceuticals, Inc. received approval from the U.S. Food and Drug Administration (FDA) for its ongoing potentially pivotal global study evaluating the efficacy and safety of Berubicin compared with Lomustine (Gleostine) administered after first-line therapy for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer.
In January 2022, Otsuka Pharmaceutical Co., Ltd. (Otsuka); its subsidiary Otsuka America Pharmaceutical, Inc.; and Lundbeck, Inc., a U.S. subsidiary of H. Lundbeck A/S in Denmark, announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) of REXULTI (brexpiprazole) for the treatment of schizophrenia in pediatric patients 13 to 17 years of age.
In April 2021, Biogen acquired the approval of the National Medical Products Administration for its product TECFIDERA for the treatment of relapsing multiple sclerosis in China.
CNS (Central Nervous System) Therapeutics Market Report Snapshots
Want to customize this report?
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATION
USA (+1) 351-333-4748
